表紙
市場調查報告書

Chloroquine(氯喹)的全球市場:2020年∼2024年

Global Chloroquine Market 2020-2024

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 931804
出版日期 內容資訊 英文 120 Pages
訂單完成後即時交付
價格
Chloroquine(氯喹)的全球市場:2020年∼2024年 Global Chloroquine Market 2020-2024
出版日期: 2020年04月02日內容資訊: 英文 120 Pages
簡介

全球Chloroquine市場在2020年∼2024年的預測期間內,預計將以3%的年複合成長率增長,達到8,612萬美元的規模。市場主要的成長要素有更多的資金投入以及對氯喹和瘧疾和類風濕關節炎的多種適應症的認識。特別是,氯喹的多種適應症有望進一步推動市場增長。

本報告提供全球Chloroquine市場相關調查分析,提供市場規模及成長率,市場趨勢,推動市場要素,課題,市場機會驗證,再加上主要供應商等相關的系統性資訊。

目錄

摘要整理

市場形勢

市場規模

  • 市場定義
  • 市場區隔分析
  • 2019年的市場規模
  • 市場預測:從2019年到2024年的預測

波特的五力分析

各應用領域市場區隔

  • 市場區隔
  • 各應用領域比較:市場規模與預測(2019-2024)
  • 瘧疾
  • 類風濕性關節炎
  • 其他
  • 各應用領域的市場機會

客戶形勢

  • 概要

各地區形勢

  • 各地區市場區隔
  • 各地區比較:市場規模與預測(2019-2024)
  • 北美
  • 歐洲
  • 亞洲
  • 其他地區
  • 主要國家
  • 各地區的市場機會

成長要素,課題及趨勢

  • 市場成長要素
  • 市場課題
  • 市場趨勢

業者情勢

  • 概要
  • 形勢的創新

供應商分析

  • 交易廠商
  • 供應商的市場定位
  • Abcam Plc
  • ADVANZ PHARMA Corp.
  • Bayer AG
  • Cadila Healthcare Ltd.
  • Ipca Laboratories Ltd.
  • Mylan NV
  • Novartis AG
  • Sanofi
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.

附錄

目錄
Product Code: IRTNTR43209

Technaviohas been monitoring the chloroquine market, and it is poised to grow by $ 86.12 mn during 2020-2024, progressing at a CAGR of 3% during the forecast period. Our reports on chloroquine market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven multiple indications of chloroquine and growing funding and awareness for malaria and rheumatic arthritis campaign. Also, multiple indications of chloroquine is anticipated to boost the growth of the market as well.

The chloroquine market analysis includes application segments and geographic landscapes

Technavio's‘ chloroquine market ’ is segmented as below:

By Application

  • Malaria
  • Rheumatoid Arthritis
  • Others

By Geographic Landscapes

  • North America
  • Europe
  • Asia and ROW

This study identifies the increasing demand and production of chloroquine by key vendors as one of the prime reasons driving the chloroquine market growth during the next few years.

Technaviopresents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources by an analysis of critical parameters. Our chloroquine market covers the following areas:

  • Chloroquine market sizing
  • Chloroquine market forecast
  • Chloroquine market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position. In line with this, this report provides a detailed analysis of several leading chloroquine market vendors that include Abcam Plc, ADVANZ PHARMA Corp., Bayer AG, Cadila Healthcare Ltd., Ipca Laboratories Ltd., Mylan NV, Novartis AG, Sanofi, Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd. Also, the chloroquine market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information, including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technaviopresents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources by an analysis of critical parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio'smarket research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

Executive Summary

  • Market Overview

Market Landscape

  • Market ecosystem
  • Value chain analysis

Market Sizing

  • Market definition
  • Market segment analysis
  • Market size 2019
  • Market outlook: Forecast for 2019 - 2024

Five Forces Analysis

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Application

  • Market segments
  • Comparison by Application
  • Malaria - Market size and forecast 2019-2024
  • Rheumatoid arthritis - Market size and forecast 2019-2024
  • Others - Market size and forecast 2019-2024
  • Market opportunity by Application

Customer landscape

  • Overview

Geographic Landscape

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • Asia - Market size and forecast 2019-2024
  • ROW - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity by geography

Drivers, Challenges, and Trends

  • Market drivers
  • Market challenges
  • Market trends

Vendor Landscape

  • Overview
  • Landscape disruption

Vendor Analysis

  • Vendors covered
  • Market positioning of vendors
  • Abcam Plc
  • ADVANZ PHARMA Corp.
  • Bayer AG
  • Cadila Healthcare Ltd.
  • Ipca Laboratories Ltd.
  • Mylan NV
  • Novartis AG
  • Sanofi
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.

Appendix

  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

Exhibits

  • 1.Key Finding 1
  • 2.Key Finding 2
  • 3.Key Finding 3
  • 4.Key Finding 5
  • 5.Key Finding 6
  • 6.Key Finding 7
  • 7.Key Finding 8
  • 8.Parent market
  • 9.Market characteristics
  • 10.Offerings of vendors included in the market definition
  • 11.Market segments
  • 12.Global - Market size and forecast 2019 - 2024 ($ million)
  • 13.Global market: Year-over-year growth 2019 - 2024 (%)
  • 14.Five forces analysis 2019 & 2024
  • 15.Bargaining power of buyers
  • 16.Bargaining power of suppliers
  • 17.Threat of new entrants
  • 18.Threat of substitutes
  • 19.Threat of rivalry
  • 20.Market condition - Five forces 2019
  • 21.Application - Market share 2019-2024 (%)
  • 22.Comparison by Application
  • 23.Malaria - Market size and forecast 2019-2024 ($ million)
  • 24.Malaria - Year-over-year growth 2019-2024 (%)
  • 25.Rheumatoid arthritis - Market size and forecast 2019-2024 ($ million)
  • 26.Rheumatoid arthritis - Year-over-year growth 2019-2024 (%)
  • 27.Others - Market size and forecast 2019-2024 ($ million)
  • 28.Others - Year-over-year growth 2019-2024 (%)
  • 29. Market opportunity by Application
  • 30.Customer landscape
  • 31.Market share by geography 2019-2024 (%)
  • 32.Geographic comparison
  • 33.North America - Market size and forecast 2019-2024 ($ million)
  • 34.North America - Year-over-year growth 2019-2024 (%)
  • 35.Europe - Market size and forecast 2019-2024 ($ million)
  • 36.Europe - Year-over-year growth 2019-2024 (%)
  • 37.Asia - Market size and forecast 2019-2024 ($ million)
  • 38.Asia - Year-over-year growth 2019-2024 (%)
  • 39.ROW - Market size and forecast 2019-2024 ($ million)
  • 40.ROW - Year-over-year growth 2019-2024 (%)
  • 41.Key leading countries
  • 42.Market opportunity by geography ($ million)
  • 43.Impact of drivers and challenges
  • 44.Vendor landscape
  • 45.Landscape disruption
  • 46.Industry risks
  • 47.Vendors covered
  • 48.Market positioning of vendors
  • 49.Abcam Plc - Overview
  • 50.Abcam Plc - Business segments
  • 51.Abcam Plc - Key offerings
  • 52.Abcam Plc - Key customers
  • 53.Abcam Plc - Segment focus
  • 54.ADVANZ PHARMA Corp. - Overview
  • 55.ADVANZ PHARMA Corp. - Business segments
  • 56.ADVANZ PHARMA Corp. - Key offerings
  • 57.ADVANZ PHARMA Corp. - Key customers
  • 58.ADVANZ PHARMA Corp. - Segment focus
  • 59.Bayer AG - Overview
  • 60.Bayer AG - Business segments
  • 61.Bayer AG - Key offerings
  • 62.Bayer AG - Key customers
  • 63.Bayer AG - Segment focus
  • 64.Cadila Healthcare Ltd. - Overview
  • 65.Cadila Healthcare Ltd. - Business segments
  • 66.Cadila Healthcare Ltd. - Key offerings
  • 67.Cadila Healthcare Ltd. - Key customers
  • 68.Cadila Healthcare Ltd. - Segment focus
  • 69.Ipca Laboratories Ltd. - Overview
  • 70.Ipca Laboratories Ltd. - Business segments
  • 71.Ipca Laboratories Ltd. - Key offerings
  • 72.Ipca Laboratories Ltd. - Key customers
  • 73.Ipca Laboratories Ltd. - Segment focus
  • 74.Mylan NV - Overview
  • 75.Mylan NV - Business segments
  • 76.Mylan NV - Key offerings
  • 77.Mylan NV - Key customers
  • 78.Mylan NV - Segment focus
  • 79.Novartis AG - Overview
  • 80.Novartis AG - Business segments
  • 81.Novartis AG - Key offerings
  • 82.Novartis AG - Key customers
  • 83.Novartis AG - Segment focus
  • 84.Sanofi - Overview
  • 85.Sanofi - Business segments
  • 86.Sanofi - Key offerings
  • 87.Sanofi - Key customers
  • 88.Sanofi - Segment focus
  • 89.Sun Pharmaceutical Industries Ltd. - Overview
  • 90.Sun Pharmaceutical Industries Ltd. - Business segments
  • 91.Sun Pharmaceutical Industries Ltd. - Key offerings
  • 92.Sun Pharmaceutical Industries Ltd. - Key customers
  • 93.Sun Pharmaceutical Industries Ltd. - Segment focus
  • 94.Teva Pharmaceutical Industries Ltd. - Overview
  • 95.Teva Pharmaceutical Industries Ltd. - Business segments
  • 96.Teva Pharmaceutical Industries Ltd. - Key offerings
  • 97.Teva Pharmaceutical Industries Ltd. - Key customers
  • 98.Teva Pharmaceutical Industries Ltd. - Segment focus
  • 99.Currency conversion rates for US$
  • 100.Research Methodology
  • 101.Validation techniques employed for market sizing
  • 102.Information sources
  • 103.List of abbreviations